Our platform drug delivery technology used with focused ultrasound will improve care for people with serious diseases. We will provide non-invasive, targeted drug delivery to the brain as well as immunotherapy, activating the body's natural defences against cancer.

Microbubbles are a proven medical product used to enhance ultrasound imaging. Researchers and clinicians are beginning to demonstrate the enormous potential of ultrasound and microbubble enhanced therapies. Artenga’s microbubble drug conjugates are produced with an on-demand, easy to use generator.

MGD5

See how the Artenga MD5 generates
ultrasound contrast agent microbubbles:

— Microbubble Drug Conjugates —

LOCATION

193 Ethel Street

Ottawa, ON, K1L 5X3

CONTACT

[email protected]

2017

The Focused Ultrasound Foundation approves a non-invasive, targeted, blood-brain barrier gene therapy delivery with our collaborators at Sunnybrook Research Institute and the University of Helsinki.  The CDNF gene therapy has shown potent neuroprotective and neurorestorive properties in brain cells damaged by Parkinson's Disease.

Dr. David Goertz of Sunnybrook Research Institute presents immunotherapy study results at the International Symposium of Therapeutic Ultrasound.  

Sunnybrook Research Institute Ontario Research Fund (ORF) project approved: Devices and Methods for Focused Ultrasound Interventions;  Principal Investigator is Dr. Kullervo Hynynen; Artenga Inc. an industry partner.

2014

The Michael J. Fox Foundation for Parkinson's Research supports a non-invasive, targeted blood brain barrier drug delivery project.  We partner with the Sunnybrook Research Institute, the NRC, and the University of Helsinki

Sunnybrook Research Institute FedDev project approval; Artenga Inc an industry partner.

2013

With the National Research Council of Canada (NRC) we co-develop a novel means to combine microbubbles and biologic drugs supported by IRAP.

Preclinical evidence that focused ultrasound and Artenga microbubbles significantly enhance chemotherapy in prostate tumour models: https://www.ncbi.nlm.nih.gov/pubmed/23284980

Preclinical tumour delivery of microbubble payload - NRC.

FedDev ARC project approved with La Cité College.

COPYRIGHT © 2017 ARTENGA INC. ALL RIGHTS RESERVED.

privacy

2016

Immunotherapy study with checkpoint inhibitors commences at Sunnybrook Research Institute.

2015

Successful pre-clinical results of non-invasive, targeted BBB  drug delivery presented at the  Michael J Fox Foundation for Parkinson's Research and a follow-on study approved.  See: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489604/

WATCH NOW

News

Partners